Creative Medical Technology Holdings, Inc. (CELZ)
(Delayed Data from NSDQ)
$3.26 USD
-0.08 (-2.40%)
Updated Aug 2, 2024 03:12 PM ET
After-Market: $3.34 +0.08 (2.45%) 7:04 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Creative Medical Technology Holdings, Inc. [CELZ]
Reports for Purchase
Showing records 21 - 40 ( 44 total )
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Focused On Higher Value Assets AlloStem And ImmCelz, Well Funded
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Enhances Clinical Grade ImmCelz Production, Independently Validated
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Engages International CRO for CELZ-201''s Phase 1/2 Type 1 Diabetes Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Three-Year StemSpine Follow-Up Supports Efficacy Durability in CLBP
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Receives IRB Approval for FDACleared Phase 1/2 Trial in T1D for CELZ-201
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
IND for AlloStem Type 1 Diabetes Treatment Cleared By FDA
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Publishes Positive Two-Year StemSpine Results in Peer-Reviewed Journal
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Positive OvaStem Three-Year Data Supports Use and Will Be Published
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Creative Medical Technology Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Partners with Greenstone Bioscience for Next Generation iPSC for ImmCelz
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J